Results 101 to 110 of about 692,862 (304)
, 2015 Yoshiaki Kubota, Kuniya Asai, Erito Furuse, Shunichi Nakamura, Koji Murai, Yayoi Tetsuou Tsukada, Wataru Shimizu Department of Medicine (Division of Cardiology), Nippon Medical School, Bunkyo-ku, Tokyo, Japan Background: Chronic obstructive ...
Kubota Y +6 more
core
BackgroundCardiovascular disease, with its feared primary presentation of acute myocardial infarction (AMI), remains the leading cause of morbidity and mortality globally.
Katarina Mars (18661267)
core +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
Beta-blockers: friend or foe in asthma?
International Journal of General Medicine, 2013 Bente Arboe, Charlotte Suppli UlrikDepartment of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, DenmarkBackground and aim: Recently, β-blockers have been suggested as a potential maintenance treatment option for asthma.
Arboe B, Ulrik CS
doaj
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization
Molecular Oncology, EarlyView.In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu +13 more
wiley +1 more source
The Beta-Blocker Heart Attack Trial
, 1981 The National Heart, Lung, and Blood Institute has taken the unusual step of prematurely ending one of its major clinical trials, the Beta-Blocker Heart Attack Trial (BHAT), on the advice of its Policy and Data Monitoring Board.
core
Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers
, 2014 To determine whether there were ocular surface changes in glaucomatous patients treated with preservatives beta-blockers who switched to preservative-free beta-blockers. METHODS: This was a prospective, longitudinal, open-labeled study.
Motolese, Ilaria +15 more
core +1 more source
Beta-adrenoblockers: treatment principles in international clinical guidelines
Кардиоваскулярная терапия и профилактика, 2005 The article contains data on beta-blocker efficacy in cardiology – the results of large, randomized clinical trials, and evidence-based clinical guidelines on beta-blocker therapy.
S. Yu. Martsevich
doaj